Beijing Centergate Subsidiary Wins Clinical Trial Approval for BDB Tablet
Stock News
Oct 07
Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Shandong Huasu Pharmaceutical Co., Ltd., recently received the Drug Clinical Trial Approval Notice for BDB Tablet issued by the National Medical Products Administration.
The drug is intended for the treatment of essential hypertension. It is a new fixed-dose combination containing known active ingredients and has not yet been marketed either domestically or internationally.
Its individual components have already demonstrated efficacy and safety in clinical practice, and their combined use is recommended by clinical guidelines.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.